Anebulo Pharmaceuticals' (ANEB) Sell (D-) Rating Reaffirmed at Weiss Ratings

Key Points

• Anebulo Pharmaceuticals has had its "sell (D-)" rating reaffirmed by Weiss Ratings, indicating analysts' continued negative outlook on the company's stock.
• Separately, the Maxim Group downgraded Anebulo from a "strong-buy" to a "hold" rating, contributing to its average rating of "hold" and a consensus price target of $5.50.
• The company recently reported earnings meeting estimates, with a projected annual EPS of -0.52, while 28.40% of the stock is currently owned by institutional investors and hedge funds.

Anebulo Pharmaceuticals (NASDAQ:ANEB - Get Free Report)'s stock had its "sell (d-)" rating reissued by analysts at Weiss Ratings in a report released on Friday,Weiss Ratings reports.

Separately, Maxim Group cut Anebulo Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Wednesday, July 23rd. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Anebulo Pharmaceuticals has an average rating of "Hold" and a consensus price target of $5.50.

Anebulo Pharmaceuticals Trading Up 0.7%

Anebulo Pharmaceuticals stock traded up $0.02 during trading on Friday, hitting $2.74. 9,391 shares of the company were exchanged, compared to its average volume of 148,241. The business's 50 day moving average is $2.46 and its 200 day moving average is $1.85. Anebulo Pharmaceuticals has a 52 week low of $0.80 and a 52 week high of $3.42. The company has a market capitalization of $112.53 million, a P/E ratio of -10.53 and a beta of -0.89.

Anebulo Pharmaceuticals (NASDAQ:ANEB - Get Free Report) last announced its quarterly earnings data on Monday, September 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.05). Equities analysts expect that Anebulo Pharmaceuticals will post -0.52 EPS for the current year.

Hedge Funds Weigh In On Anebulo Pharmaceuticals

A hedge fund recently bought a new stake in Anebulo Pharmaceuticals stock. Goldman Sachs Group Inc. acquired a new stake in shares of Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 47,954 shares of the company's stock, valued at approximately $62,000. Goldman Sachs Group Inc. owned approximately 0.12% of Anebulo Pharmaceuticals at the end of the most recent quarter. 28.40% of the stock is currently owned by institutional investors and hedge funds.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.